EUVIMEDEUVIMED entdecken
Crossref

https://impactfactor.org/PDF/IJCPR/18/IJCPR,Vol18,Issue6,Article156.pdf

Hudda Sangeeta, Choudhary Indu, Gupta Shalini, Gupta Meenu

International Journal of Current Pharmaceutical Review and Research · 30.06.2026 · 18 (06)

DOI: 10.25258/ijcpr.18.6.157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.06.2026. Verfasst von Hudda Sangeeta und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cervical cancer is the fourth most common malignancy among women worldwide and a major cause of cancer-related mortality in low- and middle-income countries, with persistent oncogenic human papillomavirus (HPV) infection as the central aetiological event. The prolonged pre-invasive phase permits early detection through Papanicolaou (Pap) smear cytology. This study evaluated the cytological spectrum of cervical lesions and correlated atypical and high-grade abnormalities with follow-up outcomes. Materials and Methods: This retrospective observational study was conducted in the Department of Pathology, MGUMST, Jaipur, between January 2025 and January 2026. Conventional Pap smears from 3650 women aged 21–65 years attending the gynaecology outpatient department were stained by the Papanicolaou technique and reported according to the 2014 Bethesda System. ASC-H, HSIL, and AGC/AIS cases were advised colposcopy and biopsy. Data were analysed using descriptive statistics.

Results

Epithelial abnormalities were detected in 700 cases (19.2%), while 2950 cases (80.8%) were negative for intraepithelial lesion or malignancy. LSIL was the most common abnormality (7.6%), followed by ASC-US (4.8%), HSIL (3.7%), ASC-H (1.9%), AGC/AIS (0.8%), and SCC (0.4%). ASC-US and LSIL predominated in younger women, whereas HSIL and malignancies were more frequent above 45 years. Follow-up of high-risk cytology yielded 76.9% CIN2+ lesions.

Conclusion

Pap smear screening remains a cornerstone of cervical cancer prevention in resource-limited settings. Age-specific screening, vigilant follow-up of high-risk cytology, and integration of HPV testing can further improve early detection and reduce the cervical cancer burden.

Zitieren

APA

Sangeeta, H., Indu, C., Shalini, G., & Meenu, G. (2026). https://impactfactor.org/PDF/IJCPR/18/IJCPR,Vol18,Issue6,Article156.pdf. International Journal of Current Pharmaceutical Review and Research, 18(06). https://doi.org/10.25258/ijcpr.18.6.157

Vancouver

Sangeeta H, Indu C, Shalini G, Meenu G. https://impactfactor.org/PDF/IJCPR/18/IJCPR,Vol18,Issue6,Article156.pdf. International Journal of Current Pharmaceutical Review and Research. 2026;18(06). doi:10.25258/ijcpr.18.6.157

BibTeX
@article{Sangeeta2026,
  author = {Sangeeta, Hudda and Indu, Choudhary and Shalini, Gupta and Meenu, Gupta},
  title = {https://impactfactor.org/PDF/IJCPR/18/IJCPR,Vol18,Issue6,Article156.pdf},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {06},
  doi = {10.25258/ijcpr.18.6.157}
}
Kostenlos starten →